跳至主要内容
临床试验/NCT05615649
NCT05615649进行中(未招募)不适用

Expanded Indications in the Pediatric BONEBRIDGE Population

Med-El Corporation11 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2023年10月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
36
试验地点
11
主要终点
Functional gain

研究概览

简要总结

This study will assess safety and efficacy of the MED-EL BONEBRIDGE Bone Conduction Implant in children under 12 years old with conductive or mixed hearing loss.

详细描述

This prospective multicenter IDE study will include 36 children implanted with the MED-EL BONEBRIDGE system at six academic medical centers across the US.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
3 Years 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Under 12 years of age
  • Unaided bone-conduction thresholds at 0.5, 1, 2, and 4 kHz better than or equal to 45 dB HL in the ear to be implanted
  • Sufficient air-bone gap (ABG) at in the ear to be implanted
  • HRCT scan that confirms sufficient bone quantity and quality to recess and fix the BCI in the ear to be implanted
  • Developmental, cognitive, and language skills needed to provide an unaided speech recognition threshold (SRT) in quiet with English spondees
  • Prior experience with acoustic or bone conduction hearing aids, unless candidate is unable to wear amplification for medical reasons
  • Parental commitment to comply with all study procedures

排除标准

  • Children under 3 years (36 months) of age
  • Chronic or non-revisable vestibular or balance disorders
  • Abnormally progressive hearing loss
  • Prior use of a hearing implant in the ear to be implanted
  • Current/ongoing use of a hearing implant in the contralateral/non-implant ear
  • Evidence that hearing loss is retrocochlear in origin
  • Medical condition that contraindicates implant surgery or anesthesia
  • Skin or scalp condition precluding use of external audio processor

研究组 & 干预措施

Study procedure

Experimental

This single-arm, repeated-measures study includes study visits at baseline, surgery, device activation, and at 1, 3, 6, and 12 months post-activation.

干预措施: MED-EL BONEBRIDGE Bone Conduction Implant (Device)

结局指标

主要结局

Functional gain

时间窗: Up to six (6) months post-activation

Postoperative improvement in aided soundfield thresholds compared to preoperative unaided soundfield thresholds

Adverse events

时间窗: Up to six (6) months post-activation

Number and proportion of subjects experiencing serious device- and surgery-related adverse events

次要结局

  • Unaided bone-conduction pure-tone average (BC-PTA)(Up to three (3) months post-activation)
  • Post-intervention quality-of-life questionnaire(Up to six (6) months post-activation)
  • Word recognition score(Up to six (6) months post-activation)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验